STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
23.21
-0.17 (-0.73%)
At close: Dec 30, 2025, 4:00 PM EST
23.21
0.00 (0.00%)
After-hours: Dec 30, 2025, 4:10 PM EST
STAAR Surgical Company Revenue
STAAR Surgical Company had revenue of $94.73M in the quarter ending September 26, 2025, with 6.93% growth. This brings the company's revenue in the last twelve months to $230.59M, down -32.42% year-over-year. In the year 2024, STAAR Surgical Company had annual revenue of $313.90M, down -2.64%.
Revenue (ttm)
$230.59M
Revenue Growth
-32.42%
P/S Ratio
4.98
Revenue / Employee
$199,301
Employees
1,157
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 27, 2024 | 313.90M | -8.51M | -2.64% |
| Dec 29, 2023 | 322.42M | 38.02M | 13.37% |
| Dec 30, 2022 | 284.39M | 53.92M | 23.40% |
| Dec 31, 2021 | 230.47M | 67.01M | 41.00% |
| Jan 1, 2021 | 163.46M | 13.28M | 8.84% |
| Jan 3, 2020 | 150.19M | 26.23M | 21.16% |
| Dec 28, 2018 | 123.95M | 33.34M | 36.80% |
| Dec 29, 2017 | 90.61M | 8.18M | 9.92% |
| Dec 30, 2016 | 82.43M | 5.31M | 6.88% |
| Jan 1, 2016 | 77.12M | 2.14M | 2.85% |
| Jan 2, 2015 | 74.99M | 2.77M | 3.84% |
| Jan 3, 2014 | 72.22M | 8.43M | 13.22% |
| Dec 28, 2012 | 63.78M | 1.02M | 1.62% |
| Dec 30, 2011 | 62.77M | 7.81M | 14.21% |
| Dec 31, 2010 | 54.96M | 3.90M | 7.63% |
| Jan 1, 2010 | 51.06M | 1.29M | 2.59% |
| Jan 2, 2009 | 49.77M | -9.59M | -16.16% |
| Dec 28, 2007 | 59.36M | 2.41M | 4.24% |
| Dec 29, 2006 | 56.95M | 5.65M | 11.01% |
| Dec 30, 2005 | 51.30M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STAA News
- 11 days ago - Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon - Business Wire
- 11 days ago - Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders - Business Wire
- 13 days ago - Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc. - PRNewsWire
- 13 days ago - Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails - Business Wire
- 13 days ago - STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value - Business Wire
- 14 days ago - Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory - Business Wire
- 14 days ago - Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction - Business Wire
- 14 days ago - Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon - Business Wire